Scientists have developed a test that uses cells from a single donor’s blood to predict whether a new drug will cause a severe reaction in humans.
The test could avert disasters like the 2006 trial of the drug TGN1412, which led to six healthy young men being admitted to intensive care with multiple organ failure. The volunteers receiving TGN1412 experienced a catastrophic inflammatory reaction called a cytokine storm.
Cytokine storm reactions are a particular worry for new biological therapies, or “biologics”, which use biological material such as antibodies. Many blockbuster drugs such as the cancer drugs Herceptin and Avastin are biologics, as are around a third of medicines in the pharmaceutical pipeline. Because these medicines are specific to humans, they can cause severe reactions that don’t materialise in animal studies, so tests on human cells are essential.
However, cytokine storm side effects are hard to predict with tests were just one cell type is used, since they depend on interactions between blood cells and endothelial cells, which form the lining of blood vessels. But because endothelial cells are deep within the body, they are normally only grown from tissue removed in surgery or post mortem, or from umbilical vessels after birth.
Because of this, current tests use endothelial cells taken from vessels of one donor, and white blood cells from a different donor. When cells from two different donors are used, one may have an immune reaction to the other, meaning the system is already primed for inflammation before the drug is added. This can result in the test falsely showing a severe immune reaction to a drug that is safe.
Researchers at Imperial College London got around this problem by isolating stem cells from the blood of a volunteer, and using them to grow endothelial cells in a dish. They then took white blood cells which they added to the donor’s own endothelial cells to recreate the unique conditions found in their blood vessels. When TGN1412 was added to the test tube, the mixture of cells released a cytokine storm, as would happen inside the body.
The new method is better as it only requires blood from one donor and doesn’t mix cells from different people, with the advantage of making a more reliable test.
Professor Jane Mitchell, from the National Heart and Lung Institute at Imperial College London, who led the study, said: “As biological therapies become more mainstream, it’s more likely that drugs being tested on humans for the first time will have unexpected and potentially catastrophic effects. We’ve used adult stem cell technology to develop a laboratory test that could prevent another disaster like the TGN1412 trial.
“Drug companies have the technical capacity to start using this test now, but we’re working on developing an off-the-shelf kit which will make it easy to use on a large scale.”
Dr Daniel Reed, the first author on the study, said: ”A further benefit of this new technology is that personalised therapies can be tested to see how safe and effective they will be for an individual.”
Read more: New test uses human stem cells to identify dangerous side effects of drugs
The Latest on: Personalised therapies
[google_news title=”” keyword=”Personalised therapies” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Personalised therapies
- Men’s health: Advantages of pelvic physical therapy for men with chronic pelvic painon May 7, 2024 at 11:55 pm
Chronic pelvic pain is a physically and emotionally distressing condition that affects men, impacting their daily lives and overall well-being. Pelvic health physical therapy offers a well-rounded ...
- Immune cell discovery ‘could lead to personalised treatment for breast cancer’on May 7, 2024 at 10:32 pm
Researchers have developed a tool to identify these anti-cancer cells which could lead to improved, personalised immunotherapies ... focused on the role of T cells – with CAR-T cell therapy being the ...
- Autism startup Kite Therapy secures $750,000 to help more children and their parentson May 7, 2024 at 5:24 pm
Melbourne-based autism support startup Kite Therapy has secured $750,000 in a pre-seed funding round led by Flying Fox Ventures.
- Personalised mRNA Vaccines - a Revolutionary New Approach in Melanoma Treatment [analysis]on May 6, 2024 at 2:10 am
A personalised mRNA vaccine to treat melanoma has now reached late-stage trials in the UK. This is just the latest step in improving the cure rate of cancer.This form of cancer therapy harnesses the ...
- Personalized mRNA vaccines: A new approach in melanoma treatmenton May 4, 2024 at 7:50 am
A personalized mRNA vaccine to treat melanoma has now reached late-stage trials in the UK. This is just the latest step in improving the cure rate of cancer.
- Hormone therapy for menopause is safer than previously thought, study findson May 2, 2024 at 1:59 pm
Massive women's health study finds most women under 60 will get some relief from menopause symptoms but it won't reduce heart risks ...
- Gene and Cell Therapy – Webinars and Online Eventson May 1, 2024 at 12:02 am
Cell and gene therapy involves extracting cells, protein or genetic material from a patient or donor and altering them to provide a highly personalised therapy. These therapies have shown potential to ...
- Experts developing immune-enhancing therapies to treat TB: Studyon April 28, 2024 at 9:33 am
Experts are developing revolutionary immune-enhancing medicines known as host-directed therapies, which employ the body's immune system to target TB, to tackle even drug-resistant strains of the ...
- Personalized 'cocktails' of antibiotics, probiotics and prebiotics hold promise in treating IBS, pilot study findson April 26, 2024 at 3:10 pm
Personalized "cocktails" of antibiotics, probiotics and prebiotics hold great promise in the treatment of a common form of irritable bowel syndrome (IBS), according to research presented at the ESCMID ...
via Bing News